Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

The stock market is a dynamic landscape constantly shaped by economic trends, technological advancements, and shifting ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

If valuations during previous corrections are used as reference points, Nifty 50 could decline to 20,510, based on CY25 ...

Mitsubishi Tanabe Pharma and bluebird bio were both bought by investors during the month, while private equity firms ...

The Genomic Valley Biotech is operating in the Bio Technology Sector. It is classified as a Smallcap stock on the BSE. What is the Market Cap of Genomic Valley Biotech? The market cap of Genomic ...

Biotech stocks represent shares in companies that ... offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...